Drug intelligence / Profile preview

Ceftriaxone + Gentamicin + Cefuroxime + Ciprofloxacin

Development stage
Unknown
Lead developer
GSK
Administration
Oral, Intravenous, Intramuscular
01

Overview

This entry describes a combination of four distinct antibiotics: ceftriaxone, gentamicin, cefuroxime, and ciprofloxacin. While these agents are not typically formulated into a single product or administered simultaneously as a routine regimen, they are often used in various combinations or sequentially to treat a broad range of bacterial infections, especially those involving multiple or resistant pathogens. * **Ceftriaxone:** A third-generation cephalosporin, broad-spectrum, with excellent penetration into meninges, eyes, and inner ear. Has a long half-life allowing for daily or twice-daily dosing. Effective against many gram-negative bacteria, including MDR Enterobacteriaceae, but less active against MSSA [2]. Efficacy correlates with bacterial growth rate [1]. * **Gentamicin:** An aminoglycoside antibiotic effective against many gram-negative bacteria. Often used for synergistic effects with other antibiotics. Like ceftriaxone, shows better efficacy against rapidly growing bacteria [1]. Dosing is weight-based and requires monitoring due to potential toxicity. * **Cefuroxime:** A second-generation cephalosporin, resistant to beta-lactamase, with broad-spectrum activity against gram-positive and gram-negative organisms. Used for respiratory, skin, urinary tract infections, gonorrhea, and early Lyme disease [5]. * **Ciprofloxacin:** A fluoroquinolone antibiotic with broad-spectrum activity against gram-negative and some gram-positive bacteria. Less dependent on bacterial growth rate than ceftriaxone or gentamicin [1]. Maintains significant bacterial load reduction even during slow bacterial growth [1]. Combinations involving these antibiotics are used for various infections, including complicated UTIs/pyelonephritis, severe respiratory infections, bacteremia, and infections where broad empirical coverage is needed or specific resistant pathogens are suspected.

02

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)16S rRNA (16S ribosomal RNA)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Ceftriaxone + Gentamicin + Cefuroxime + Ciprofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceftriaxone + Gentamicin + Cefuroxime + Ciprofloxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call